Tizanidine
Product Images NDC 71610-345

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Tizanidine (NDC 71610-345). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 2 mg (71610 0345 09)

Label for Tizanidine, USP 2mg tablets, package containing 9000 tablets. The product is labeled by Aphena Pharma Solutions - Tennessee, LLC. The label includes storage instructions, manufacturing details by Alkaloida Chemical Company Zrt. in Hungary, and notes that the medication is RX only.*

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Tizanidine-1 (Tizanidine 1)

Chemical structure of Tizanidine hydrochloride, showing a chlorinated bicyclic structure with attached nitrogen and sulfur atoms and an imidazoline ring.*

FDA Label Image

Tizanidine-2 (Tizanidine 2)

A pharmacokinetic graph showing plasma concentration of Tizanidine (ng/mL) over time (hours from dosing) for 4 mg tablets and capsules, both with food and without food. The chart compares the absorption curves of these four conditions, illustrating peak concentration and decline over 24 hours.*

FDA Label Image

Tizanidine-3 (Tizanidine 3)

A line graph showing improvement in Ashworth Score over 6 hours post-dose comparing 16 mg tizanidine, 8 mg tizanidine, and placebo. The graph includes error bars indicating variability at each time point for the three groups.*

FDA Label Image

Tizanidine-4 (Tizanidine 4)

A line graph showing improvement in Ashworth Score over three time points: End of Titration (Study Week 3), End of Maintenance (Study Week 7), and Endpoint (Last Observation Carried Forward). The graph compares Tizanidine (mean dose 28.8 mg) and placebo, with Tizanidine showing greater improvement scores at all points.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.